… Molnupiravir is available through an EUA for treatment of adults 18 years of age and older …
of symptom onset, and for whom alternative treatment options are not available or appropriate. …

… cohort study, including nonhospitalized patients aged 18–… treatment with other approved
medications for COVID-19 such as monoclonal antibody, convalescent plasma, or molnupiravir …

… non-hospitalized adults with COVID-19. While no clinical benefits have been observed with
molnupiravir … early (i) molnupiravir or (ii) nirmatrelvir/ritonavir treatment at public hospitals …

… , nonhospitalized adults with mild to moderate disease who had at least 1 risk factor for disease
progression, MPV treatment … molnupiravir and 2661 propensity score-matched controls, …

… Molnupiravir plus usual care versus usual care alone as early treatment for adults with
COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-…

… Molnupiravir,” “COVID-19,” and “efficacy.” This meta-analysis included studies that
compared the effectiveness of molnupiravir with a placebo for COVID-19 treatment… of non-hospitalized …

… , the viral RNA incorporates Molnupiravir which leads to … of Molnupiravir versus placebo in
non-hospitalized adults with … was to determine the efficacy of Molnupiravir by evaluating the …

… Molnupiravir plus usual care versus usual care alone as early treatment for adults with
COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-…

… to be used in the treatment of hospitalized children ≥12 years and adults with COVID-19, …
Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N Engl J Med. 2022;…

… both nirmatrelvir and molnupiravir can be used to treat nonhospitalized patients who are
at … BA.1 and BA.2 among vaccinated adults with relatively low risk of progressing to severe …